NCT06168370 (POP ATLANTIS) is a NA clinical trial of CT guided strategy in Severe Aortic Valve Stenosis, sponsored by St. Antonius Hospital.

Who is sponsoring NCT06168370?

NCT06168370 is sponsored by St. Antonius Hospital.

What drugs are being tested in NCT06168370?

Interventions in NCT06168370: CT guided strategy.

What condition does NCT06168370 study?

NCT06168370 studies Severe Aortic Valve Stenosis.

Is NCT06168370 still recruiting?

NCT06168370 is currently recruiting now. Last updated 25 April 2024.

Last reviewed 2024-04-25 · How we verify

NCT06168370: POP ATLANTIS

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Personalized, CT-guided Antithrombotic Therapy Versus Lifelong Single Antiplatelet Therapy to Reduce Thromboembolic and Bleeding Events in Non-atrial Fibrillation Patients After Transcatheter Aortic Valve Implantation

Recruiting now NA Last updated 25 April 2024

What this trial tests

NA trial testing CT guided strategy in Severe Aortic Valve Stenosis in 2,500 participants. Currently enrolling.

Timeline

1 December 2023

Primary endpoint
1 January 2028

1 June 2028

Quick facts

Lead sponsor	St. Antonius Hospital
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	2,500
Start date	1 December 2023
Primary completion	1 January 2028
Estimated completion	1 June 2028
Sites	1 location across Netherlands

Drugs / interventions tested

CT guided strategy

Conditions studied

Severe Aortic Valve Stenosis — all drugs for Severe Aortic Valve Stenosis →

Sponsor

St. Antonius Hospital

Who can join

Adults 18 to 110, any sex, with Severe Aortic Valve Stenosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The POPular ATLANTIS trial aims to investigate CT-guided antithrombotic therapy compared to lifelong single antiplatelet therapy after a transcatheter aortic valve implantation (TAVI) procedure. Only patients without an indication for anticoagulants will be included in this trial. Currently, lifelong single antiplatelet therapy (mostly aspirin) is considered the standard of care for these patients. However, this approach poses a bleeding risk with only a minimal reduction in thromboembolic events. After 3 months, a CT scan will be conducted to assess the presence of thrombosis on the newly implanted TAVI valve. Based on the results of a 4D CT scan, the decision will be made whether the patient should receive no anticoagulant or antithrombotic therapy with apixaban. CT-guided antithrombotic therapy holds the potential for a greater reduction in thromboembolic events without increasing the bleeding risk.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Antithrombotic therapy for transcatheter structural heart intervention.
Guedeney P, Rodés-Cabau J, Ten Berg JM, Windecker S, et al · · 2024 · cited 6× · PMID 39155752 · DOI 10.4244/eij-d-23-01084
Anti-Thrombotic Therapy Following Transcatheter Structural Heart Intervention.
Tartaglia F, Antonelli G, Gabrielli A, Gitto M, et al · · 2026 · PMID 42074976 · DOI 10.3390/jcm15083175
Thrombotic Versus Bleeding Risk After Transcatheter Aortic Valve Implantation
Fotoula K, Ibrahem A, Harfoush A, Hussain H, et al · · 2026
Optimal antithrombotic therapy after transcatheter aortic valve replacement: a comprehensive review.
Thanh NVT, Hong MK, Ko YG. · · 2025 · PMID 40129765 · DOI 10.3389/fcvm.2025.1528071
Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation
Pallante F, Costa F, Garcia Ruiz V, Vizzari G, et al · · 2024

Verify or expand the search:

Other recruiting trials for Severe Aortic Valve Stenosis

Currently open trials in the same condition.

NCT07335900 — A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis · NA · recruiting
NCT06859255 — In-vitro Benchmarking of Currently Available Heart Valve Prostheses for Surgical and Percutaneous Treatment of Aortic St · NA · recruiting
NCT06168123 — Future Optimal Research and Care Evaluation - Aortic Stenosis · recruiting
NCT05552352 — VRAP-Heart - Virtual Reality Assisted Patient Empowerment for Interventions in Structural Heart Disease · NA · recruiting

Other St. Antonius Hospital trials

Trials by the same sponsor.

NCT07398118 — CRYO-1: Cryoablation in Elderly Patients With Early-Stage Breast Cancer. · NA · not yet recruiting
NCT07414446 — Non-Invasive Detection of Pulmonary Right-to-Left Shunts Using the SONAS Ultrasound Device · NA · recruiting
NCT07309848 — Hip Fracture Surgery Timing and Blood Transfusion Risk in Patients on DOACs · recruiting
NCT07157358 — Online Medical Hypnosis Exercises to Improve Mental Health in Primary School Children and Prevent Future Mental Health I · NA · recruiting
NCT06960174 — Virtual Renality: Assessing the Impact of Virtual Reality on Preoperative Planning in Renal Cancer Surgery · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06168370 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by St. Antonius Hospital
Last refreshed: 25 April 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06168370.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing